Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14+
SponsorUniversity of Texas Southwestern Medical Center
About this trial
This is an observational study to deeply phenotype the disorder of POTS using multiple testing modalities.
Eligibility criteria
Qualifiers
Age ≥ 14 years, able to provide informed consent (assent with parental consent for age < 18) and comply with procedures
Meets consensus criteria for POTS: (1) sustained increase in heart rate ≥ 30 bpm above supine baseline within 10 min of quiet standing or upright tilt (≥ 40 bpm in individuals 12 to 19 years of age) OR sustained upright HR (heart rate) >120 bpm, (2) absence of orthostatic hypotension, (3) symptoms with standing that improve with sitting or lying down, (4) resting supine heart rate < 100 bpm, (5) orthostatic symptoms present for at least 6 months
Stable oral medication regimen for at least 14 days
Healthy women, age 18 - 30 years, able to provide informed consent and comply with study procedures
Disqualifiers
Use of amphetamine-type stimulants, diuretics, selective norepinephrine reuptake inhibitor, anticholinergic medications (including tricyclic antidepressant medications), fludrocortisone, desmopressin in past 14 days
Use of other autonomic drugs (adrenergic agents, pyridostigmine, droxidopa, triptans, ivabradine) in past 48 hours
Currently receiving IVIG (Intravenous immunoglobulin), subcutaneous IgG (Immunoglobulin G), or any investigational medication (in past year)
Infusion of iv fluids in past 7 days
Trial design
Treatments tested in this trial
- multimodal diagnostic testing
Treatment groups
350 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Texas Southwestern Medical Center
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov